REQUEST A DEMO
Total
USD $0.00
Search more companies

Medites Pharma, Spol. S R.O. (Czech Republic)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Medites Pharma, Spol. S R.O. Profile Updated: October 29, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Medites Pharma, Spol. S R.O. is based in Czech Republic. The head office is in Roznov pod Radhostem. The company operates in the Pharmaceutical Preparation Manufacturing sector. It was established on April 10, 1992. Medites Pharma, Spol. S R.O. currently employs 1 - 5 (2024) people. There was a net sales revenue drop of 3.54% reported in Medites Pharma, Spol. S R.O.’s latest financial highlights for 2023. During that time, Medites Pharma, Spol. S R.O.’s total assets decreased by 15.45%. In 2023, Medites Pharma, Spol. S R.O.’s net profit margin increased by 4.57%.

Headquarters
1. maje 2635
Roznov pod Radhostem; Zlinsky; Postal Code: 75661

Contact Details: Purchase the Medites Pharma, Spol. S R.O. report to view the information.

Basic Information
Total Employees:
Purchase the Medites Pharma, Spol. S R.O. report to view the information.
Outstanding Shares:
Purchase the Medites Pharma, Spol. S R.O. report to view the information.
Registered Capital:
Purchase the Medites Pharma, Spol. S R.O. report to view the information.
Incorporation Date:
April 10, 1992
Key Executives
Purchase this report to view the information.
Legal Representative
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Medites Pharma, Spol. S R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
-3.54%
Total operating revenue
-3.54%
Operating profit (EBIT)
-35.9%
EBITDA
-39.79%
Net Profit (Loss) for the Period
47.55%
Total assets
-15.45%
Total equity
-16.17%
Operating Profit Margin (ROS)
-3.08%
Net Profit Margin
4.57%
Return on Equity (ROE)
2.47%
Quick Ratio
4.21%
Cash Ratio
0.29%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?